KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis

John R. Graybill, Laura K. Najvar, Annette Fothergill, Thomas Hardin, Michael Rinaldi, Chris Lambros, Steven L. Regen

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

KY-62 is a water-soluble analog of amphotericin B. In vitro testing of five clinical isolates of Candida albicans showed KY-62 to have potency similar to that of amphotericin B. KY-62 was administered to mice infected intravenously with C. albicans. In vivo, KY-62 was effective in immunocompetent mice, with potency similar to that of amphotericin B. KY-62 was well tolerated up to 30 mg/kg of body weight per dose, an amount that would be lethal with amphotericin B. KY-62 was less effective in mice rendered neutropenic with 5-fluorouracil. The addition of flucytosine had little effect. KY-62 may have potential for clinical development.

Original languageEnglish (US)
Pages (from-to)147-150
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume42
Issue number1
DOIs
StatePublished - Jan 1998

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis'. Together they form a unique fingerprint.

  • Cite this

    Graybill, J. R., Najvar, L. K., Fothergill, A., Hardin, T., Rinaldi, M., Lambros, C., & Regen, S. L. (1998). KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis. Antimicrobial agents and chemotherapy, 42(1), 147-150. https://doi.org/10.1128/aac.42.1.147